This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2012 by Medicine, National University Hospital, Singapore.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Tan Tock Seng Hospital
Information provided by (Responsible Party):
Medicine, National University Hospital, Singapore
ClinicalTrials.gov Identifier:
NCT01720940
First received: October 21, 2012
Last updated: November 1, 2012
Last verified: November 2012
  Purpose

This study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion.

This study will recruit 220 subjects from 2 hospitals over a period of 3 years.

Participants are invited if they have an infection that requires prolonged vancomycin therapy (> more than 10 days).


Condition Intervention
Infections Requiring Prolonged Duration (>10 Days) of Vancomycin Drug: continuous vancomycin infusion Drug: intermittent vancomycin infusion

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin

Resource links provided by NLM:


Further study details as provided by Medicine, National University Hospital, Singapore:

Primary Outcome Measures:
  • nephrotoxicity [ Time Frame: occurring any time while on vancomycin treatment up to 14 days post treatment completion ]
    nephrotoxicity as defined by the acute kidney injury network (AKIN) criteria using only serum creatinine criteria


Secondary Outcome Measures:
  • biomarkers for detection of early nephrotoxicity [ Time Frame: measured weekly from the date of randomization until 14 days post completion of vancomycin ]
    serum and urine NGAL and cystatin C


Estimated Enrollment: 220
Study Start Date: October 2012
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: continuous vancomycin infusion Drug: continuous vancomycin infusion
24-hour continuous infusion of vancomycin
Active Comparator: intermittent vancomycin infusion
vancomycin in this arm will be administered as intermittent infusion
Drug: intermittent vancomycin infusion

  Eligibility

Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults aged 21-80 years
  • Documented infection requiring prolonged (> 10 days) of vancomycin therapy
  • Creatinine clearance > 50 ml/min (using Cockroft-Gault equation)

Exclusion Criteria:

  • Patient already received 7 days or more of vancomycin therapy
  • Pregnancy
  • Severe burns > 40% body surface area
  • Spinal cord injuries
  • Participation in another interventional trial in previous 30 days
  • Inability to obtain informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01720940

Contacts
Contact: Shire Yang Tan 97989001 shire_yang_tan@nuhs.edu.sg

Locations
Singapore
National University Hospital Recruiting
Singapore, Singapore
Contact: Shire Yang Tan    97989001    shire_yang_tan@nuhs.edu.sg   
Principal Investigator: Dale Fisher         
Sponsors and Collaborators
National University Hospital, Singapore
Tan Tock Seng Hospital
  More Information

Responsible Party: Medicine, Division of Infectious Diseases, National University Hospital, Singapore
ClinicalTrials.gov Identifier: NCT01720940     History of Changes
Other Study ID Numbers: NUHID-001
Study First Received: October 21, 2012
Last Updated: November 1, 2012

Additional relevant MeSH terms:
Vancomycin
Anti-Bacterial Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on July 26, 2017